Palisade Bio, Inc. (PALI)

Palisade Bio's stock price was $1.80 as of May 8, 2026, a decrease of 23.4% since January 1, 2026. The stock has traded between $0.53 and $2.86 in the past 52 weeks. In March 2026, the company announced positive topline data from its Phase 1b clinical study of PALI-2108 in fibrostenotic Crohn's disease. The company also participated in several healthcare conferences and reported its third-quarter 2024 financial results in November 2025.

Demand seasonality is not directly applicable to Palisade Bio, as a clinical-stage biopharmaceutical company. Demand for its product candidates is driven by clinical trial progress, regulatory approvals, and efficacy in treating specific patient populations. The company's revenue generation is tied to research and development milestones rather than seasonal consumer demand.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for autoimmune, inflammatory, and fibrotic diseases, particularly gastrointestinal conditions. The company's strategy involves a prodrug platform designed to activate therapeutic agents selectively, aiming to stimulate the innate immune system while minimizing systemic exposure. Its pipeline centers on gut-targeted oral candidates, including PALI-2108 for IBD and PDS0108 for advanced solid tumors.

Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations, and biotechnology partners. The company's headquarters are located in Carlsbad, California, with some sources also mentioning Denver, Colorado.

Palisade Bio's brand reputation is tied to its clinical trial progress and analyst coverage. The company has an average recommendation of "Moderate Buy" from analysts, with an average twelve-month price target of $10.20. Positive data from the Phase 1b clinical study of PALI-2108 and presentations at healthcare conferences contribute positively to its reputation. There were no material, long-running controversies unique to Palisade Bio central in public archives through mid-2024.

Palisade Bio has a diverse ownership structure, including institutional and individual investors. Institutional owners hold approximately 11.79% of the stock, with major shareholders including Perceptive Advisors Llc and Commodore Capital Lp. Individual investors are the largest owners, holding 59% of Palisade Bio. Insiders own less than 1% of Palisade Bio, Inc.